Aegerion Pharmaceuticals Inc (AEGR.O)

AEGR.O on Nasdaq

1:00pm EST
Price Change (% chg)

$-0.77 (-3.53%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for AEGR.O


Aegerion Pharmaceuticals, Inc. (Aegerio) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders. As of December 31, 2011, the Company developed its first product candidate, lomitapide, as an oral, once-a-day treatment for patients with a inherited lipid disorder... (more)


Beta: 0.85
Market Cap (Mil.): $621.04
Shares Outstanding (Mil.): 28.44
Dividend: --
Yield (%): --


  AEGR.O Industry Sector
P/E (TTM): -- 37.69 38.55
EPS (TTM): -1.54 -- --
ROI: -18.23 17.92 17.25
ROE: -32.65 18.73 18.17
Search Stocks

BRIEF-Astrazeneca sells Myalept to Aegerion

* Entered into a definitive agreement with aegerion pharmaceuticals, inc. To divest myalept (metreleptin for injection), Source text for Eikon: Further company coverage:

06 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: ValuEngine, Inc.
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks